Navigation Links
New Type of Stent Appears Safe, Effective
Date:9/1/2008

Artery-opening device emits drug from a biodegradable polymer

MONDAY, Sept. 1 (HealthDay News) -- One of a "new generation" of artery-opening, drug-eluting stents appears equally effective as older models in boosting outcomes for heart patients, a new head-to-head study shows.

Stents are tiny mesh tubes inserted into arteries to keep blood flowing. Drug-eluting stents emit medicines that help prevent reclosure. The latest form of drug-eluting stents releases the drugs from a biodegradable polymer coating.

In the new study, published early online Sept. 1 in The Lancet, researchers in Switzerland compared one such stent, which releases the drug biolimus, against a standard drug-eluting stent releasing sirolimus. Adult heart patients with chronic stable coronary artery disease or acute coronary syndromes were randomized to receive either of the two stents. A subset (427 patients) later underwent angiography to see how well the stent was performing.

After nine months of follow-up, researchers led by Professor Stephan Windecker of Bern University Hospital reported that biolimus-eluting stents were as effective as the sirolimus stent in terms of the number of patients who experienced a combination of cardiac death, heart attack or need for a repeat revascularization procedure of the treated vessel -- 9 percent for the biolimus group and 11 percent for those receiving the sirolimus stent.

There were also no significant difference between the biolimus and sirolmus stent groups when each event was looked at separately: cardiac death (1.6 percent vs. 2.5 percent, respectively), heart attack (5.7 percent vs. 4.6 percent) and repeat procedures (4.4 percent vs. 5.5 percent). Each stent also performed similarly in terms of the percentage of vessel diameter that reclosed over the nine-month period, the team noted.

According to the authors, the study, "establishes the non-inferiority" of the newer biolimus-eluting stent.

But in an editorial, Dr. Ron Waksman, of Washington Hospital Center, Washington, D.C., was more cautious. "Before we become overly enthused with new-generation drug-eluting stents, we should call for new-generation trial designs that will enable us to assess whether or not these new stents are necessarily better," he wrote.

The study, which was expected to be presented Monday at the European Society of Cardiology meeting in Munich, was funded by the maker of the biolimus stent, Biosensors Europe SA, Switzerland.

More information

There's more on stents and stenting at the American Heart Association.



-- E.J. Mundell



SOURCE: The Lancet, news release, Sept. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. MD On-Line Achieves CAQH CORE(TM) Certification for Consistent Healthcare Administrative Data Exchange
2. NYC first: Complex aneurysm treated using new fenestrated endograft stent
3. Drug-Coated Stents Reduce Repeat Artery Procedures
4. How to use endoscopic stent for biliary stricture trauma?
5. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
8. More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
9. Study analyzed SYMBICORT in children with persistent asthma
10. High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
11. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: